Cardiol Therapeutics | WebDisclosure

PRESS RELEASE

published on 06/14/2024 at 14:52, 1 year 8 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research increases Cardiol Therapeutics Inc's price target to USD8.50 in Buy recommendation after positive results from phase II trial of CardiolRx for recurrent pericarditis treatment

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Phase II Trial CardiolRx
PRESS RELEASE

published on 02/27/2024 at 14:16, 2 years ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates BUY recommendation on Cardiol Therapeutics Inc. FDA grants Orphan Drug Designation for CardiolRx in pericarditis treatment. Positive phase II study results expected in Q2 2024

FDA Cardiol Therapeutics Inc First Berlin Equity Research Orphan Drug Designation Pericarditis
BRIEF

published on 02/27/2024 at 14:16, 2 years ago

Cardiol Therapeutics Receives FDA Orphan Drug Designation for CardiolRx

FDA Investment Orphan Drug Designation Cardiol Therapeutics Pericarditis
BRIEF

published on 02/27/2024 at 14:16, 2 years ago

Cardiol Therapeutics obtient la désignation de médicament orphelin par la FDA pour CardiolRx

Investissement FDA Orphan Drug Designation Cardiol Therapeutics Pericardite
PRESS RELEASE

published on 01/19/2024 at 12:41, 2 years 1 month ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research has published an update on Cardiol Therapeutics Inc., reaffirming its BUY recommendation and maintaining the price target of USD 3.60. The report highlights the progress in patient recruitment for CardiolRx's two lead indications, acute myocarditis (AM) and recurrent pericarditis (RP), with expectations of significant near-term catalysts for the stock. Analyst Christian Orquera remains optimistic about the company's investment potential. For the full analysis, visit the link provided.

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Patient Recruitment Investment Potential
PRESS RELEASE

published on 08/30/2023 at 15:06, 2 years 5 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
PRESS RELEASE

published on 05/24/2023 at 13:01, 2 years 9 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
PRESS RELEASE

published on 04/11/2023 at 15:26, 2 years 10 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy

Published on 02/27/2026 at 22:00, just now

MWC 2026: Amdocs Collaborates with Google Cloud to Accelerate AI Adoption and Power the Agentic Telco Contact Center
Published on 02/27/2026 at 17:45, 4 hours 15 minutes ago

Sparta Capital Ltd. Announces Filing of Annual Financial Statements
Published on 02/27/2026 at 17:41, 4 hours 19 minutes ago

Nepra Foods Inc. Achieves First Quarterly Net Income in Company History; Reports Financial Results for the Quarter Ending December 31, 2025, Revenue Increases 51% to $5,973,147, Gross Profit Rises to $1,855,624 (31.1% Margin), Net Income of $84,966
Published on 02/27/2026 at 16:00, 6 hours ago

Trans Canada Gold Announces Plans for Exploration and Drilling on its Harrison Lake Gold Project, Lays Out Detailed 2026 Drilling Program Targeting Gold
Published on 02/27/2026 at 14:30, 7 hours 30 minutes ago

Solitario Attending PDAC 2026 at Booth 2422A and Participating in One-on-One Meetings

View all ACCESSWIRE

Published on 02/27/2026 at 19:30, 2 hours 30 minutes ago

EUROPLASMA: Modification des caractéristiques des tranches 22 et 23 d’OCABSA
Published on 02/27/2026 at 18:25, 3 hours 35 minutes ago

TVR-Total Voting Rights
Published on 02/27/2026 at 18:11, 3 hours 48 minutes ago

POS-Transaction in Own Shares
Published on 02/27/2026 at 18:00, 4 hours ago

Halfords Group PLC: Total Voting Rights
Published on 02/27/2026 at 17:59, 4 hours 1 minute ago

EQS-Adhoc: 4finance completes sale of TBI Bank to Advent International

View all EQS

Published on 02/27/2026 at 18:02, 3 hours 57 minutes ago

AXA: Execution of a share repurchase agreement in relation to AXAs share buy-back program of up to Euro 1.25 billion
Published on 02/27/2026 at 18:02, 3 hours 57 minutes ago

AXA: Conclusion d’une convention de rachat d’actions dans le cadre du programme de rachat d’actions d’AXA
Published on 02/27/2026 at 18:00, 4 hours ago

Augmentation de capital réservée
Published on 02/27/2026 at 17:45, 4 hours 15 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2025
Published on 02/27/2026 at 17:45, 4 hours 15 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of January 31, 2026

View all LES ECHOS COMFI WIRE

News